Seer (SEER) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Board unanimously rejected a revised unsolicited acquisition proposal from two stockholders, citing it was not in the best interest of the company, customers, employees, or stockholders.
Leadership reaffirmed confidence in current strategy and ongoing business operations, emphasizing continued focus on platform advancement and customer relationships.
Forward-looking statements highlight ongoing commitment to strategic opportunities and capital deployment objectives, with risks and uncertainties noted.
Voting matters and shareholder proposals
Proxy solicitation is underway for the 2026 Annual Meeting, with directors and executive officers participating.
Stockholders will receive a BLUE proxy card and are encouraged to review the 2026 Proxy Statement and related materials when available.
Board of directors and corporate governance
Board members involved in proxy solicitation include Omid Farokhzad, Meeta Gulyani, Robert Langer, Terrance McGuire, Deep Nishar, Isaac Ro, Nicolas Roelofs, and David Horn.
Changes in security holdings for directors and officers since the last proxy statement are documented in recent SEC filings.
Latest events from Seer
- Board unanimously rejects revised unsolicited acquisition proposal; shareholder vote solicited.SEER
Proxy filing27 Apr 2026 - Board rejects revised unsolicited proposal, affirms strategy, and prepares for 2026 proxy vote.SEER
Proxy filing27 Apr 2026 - Received unsolicited acquisition proposal and director nominations; board review underway.SEER
Proxy filing14 Apr 2026 - Acquisition proposal and board nominations prompt detailed review ahead of 2026 Annual Meeting.SEER
Proxy filing13 Apr 2026 - Strong growth, innovation, and new detector tech set the stage for future expansion.SEER
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - 2025 revenue rose 17% to $16.6M, with improved margins and a 67% increase in installed base.SEER
Q4 202526 Feb 2026 - Q2 revenue fell 23% to $3.1M; guidance cut, but cash remains strong and pipeline is growing.SEER
Q2 20242 Feb 2026 - High-impact publications and scientific validation drive optimism for growth in 2025.SEER
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Proteograph's robust, scalable platform accelerates unbiased biomarker discovery and scientific adoption.SEER
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026